Alnylam Pharmaceuticals Inc (ALNY)vsArrowhead Pharmaceuticals Inc (ARWR)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
ARWR
Arrowhead Pharmaceuticals Inc
$60.77
+8.00%
HEALTHCARE · Cap: $8.51B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 240% more annual revenue ($3.71B vs $1.09B). ARWR leads profitability with a 18.5% profit margin vs 8.5%. ARWR trades at a lower P/E of 38.0x. ARWR earns a higher WallStSmart Score of 58/100 (C).
ALNY
Hold49
out of 100
Grade: D+
ARWR
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
-71.1%
Fair Value
$35.97
Current Price
$60.77
$24.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Every $100 of equity generates 76 in profit
Revenue surging 104.6% year-over-year
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Premium valuation, high expectations priced in
Trading at 14.7x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ARWR
The strongest argument for ARWR centers on Return on Equity, Revenue Growth. Profitability is solid with margins at 18.5% and operating margin at 15.5%. Revenue growth of 104.6% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : ARWR
The primary concerns for ARWR are P/E Ratio, Price/Book, Altman Z-Score.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while ARWR is a growth play — different risk/reward profiles.
ARWR carries more volatility with a beta of 1.30 — expect wider price swings.
ARWR is growing revenue faster at 104.6% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ARWR scores higher overall (58/100 vs 49/100), backed by strong 18.5% margins and 104.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Arrowhead Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?